

Supplementary Table S2. TEAEs occurring in >10% of patients in any group (safety population)

TEAE, n (%)	Normal		Liver Impairment					
	Group A (n=540)		Group B (n=292)		Group C (n=440)		Group D (n=34)	
	All	Grade ≥3	All	Grade ≥3	All	Grade ≥3	All	Grade ≥3
Any TEAE	520 (96.3)	328 (60.7)	278 (95.2)	209 (71.6)	424 (96.4)	326 (74.1)	34 (100)	29 (85.3)
Neutropenia	260 (48.2)	216 (40.0)	168 (57.5)	147 (50.3)	253 (57.5)	222 (50.5)	25 (73.5)	24 (70.6)
Alopecia	204 (37.8)	0	131 (44.9)	0	183 (41.6)	0	16 (47.1)	0
Nausea	140 (25.9)	2 (0.4)	96 (32.9)	1 (0.3)	143 (32.5)	5 (1.1)	9 (26.5)	0
Leukopenia	145 (26.9)	70 (13.0)	72 (24.7)	42 (14.4)	121 (27.5)	66 (15.0)	11 (32.4)	8 (23.5)
Asthenia	96 (17.8)	20 (3.7)	56 (19.2)	16 (5.5)	101 (23.0)	30 (6.8)	10 (29.4)	3 (8.8)
Decreased appetite	89 (16.5)	0	48 (16.4)	3 (1.0)	82 (18.6)	5 (1.1)	9 (26.5)	0
Diarrhea	84 (15.6)	5 (0.9)	49 (16.8)	1 (0.3)	75 (17.1)	1 (0.2)	9 (26.5)	0
Fatigue	122 (22.6)	10 (1.9)	75 (25.7)	11 (3.8)	106 (24.1)	18 (4.1)	8 (23.5)	0
Pyrexia	84 (15.6)	1 (0.2)	52 (17.8)	0	81 (18.4)	2 (0.5)	9 (26.5)	0
Anemia	90 (16.7)	3 (0.6)	53 (18.2)	11 (3.8)	96 (21.8)	16 (3.6)	7 (20.6)	2 (5.9)
Constipation	68 (12.6)	1 (0.2)	62 (21.2)	1 (0.3)	90 (20.5)	4 (0.9)	5 (14.7)	0
Vomiting	69 (12.8)	2 (0.4)	51 (17.5)	1 (0.3)	80 (18.2)	5 (1.1)	7 (20.6)	0

Headache	80 (14.8)	4 (0.7)	56 (19.2)	2 (0.7)	79 (18.0)	2 (0.5)	4 (11.8)	0
Dyspnea	65 (12.0)	17 (3.2)	37 (12.7)	10 (3.4)	63 (14.3)	19 (4.3)	6 (17.7)	1 (2.9)
Hypokalemia	21 (3.9)	5 (0.9)	12 (4.1)	4 (1.4)	28 (6.4)	9 (2.1)	6 (17.7)	3 (8.8)
Weight, decreased	41 (7.6)	2 (0.4)	45 (15.4)	0	77 (17.5)	0	6 (17.7)	1 (2.9)
Peripheral sensory neuropathy	84 (15.6)	16 (3.0)	35 (12.0)	9 (3.1)	46 (10.5)	12 (2.7)	5 (14.7)	1 (2.9)
Hyperbilirubinemia	3 (0.6)	0	5 (1.7)	1 (0.3)	9 (2.1)	2 (0.5)	5 (14.7)	2 (5.9)
Lacrimation, increased	17 (3.2)	0	26 (8.9)	1 (0.3)	30 (6.8)	1 (0.2)	5 (14.7)	0
Stomatitis	25 (4.6)	1 (0.2)	18 (6.2)	1 (0.3)	34 (7.7)	4 (0.9)	5 (14.7)	1 (2.9)
Back pain	75 (13.9)	7 (1.3)	39 (13.4)	4 (1.4)	51 (11.6)	6 (1.4)	4 (11.8)	0
Bone pain	47 (8.7)	3 (0.6)	39 (13.4)	10 (3.4)	55 (12.5)	15 (3.4)	2 (5.9)	0
Arthralgia	66 (12.2)	5 (0.9)	33 (11.3)	1 (0.3)	42 (9.6)	1 (0.2)	2 (5.9)	0
Cough	60 (11.1)	2 (0.4)	35 (12.0)	1 (0.3)	51 (11.6)	2 (0.5)	4 (11.8)	0
Paraesthesia	37 (6.9)	10 (1.9)	27 (9.3)	2 (0.7)	38 (8.6)	3 (0.7)	4 (11.8)	0
Dry mouth	21 (3.9)	0	12 (4.1)	0	19 (4.3)	0	4 (11.8)	0
Epistaxis	6 (1.1)	0	4 (1.4)	0	10 (2.3)	0	4 (11.8)	0
ALT, increased	29 (5.4)	12 (2.2)	33 (11.3)	14 (4.8)	41 (9.3)	15 (3.4)	1 (2.9)	0
Pain in extremity	56 (10.4)	2 (0.4)	32 (11.0)	1 (0.3)	45 (10.2)	5 (1.1)	0	0

Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TEAE, treatment-emergent adverse event.